A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology.

A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology.
Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots.
Imperial.Tech.Pitch: Affordable technologies for an ageing society centred on the premise that within 20 years, there will be 25% fewer taxpayers to pensioners in the UK than in 2020.
BWSQ is the leading tool for assessing benzodiazepine withdrawal symptoms, used in a number of clinical trials involving benzodiazepines.
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier.
Learn about our programme of events and sign up to be alerted for future events
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim.
A portfolio of human colorectal adenocarcenoma cell lines including primary cell lines isolated from patients (of various Duke’s stages and histological grades) in addition to cloned cells lines genetically modified to highly express alpha integrin domains.
MyoLoop is a device that can simulate pathological conditions (e.g. hypertension), to study their progression, and the effects of therapeutic interventions on them.
Proposed use Research into Charcot-Marie Tooth Disease (Type 1A). Research into autoimmune neurological disorders would be the main target market. Problem addressed Construction of models of human inherited diseases is particularly important for testing gene therapy...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.